Sunday, 29 January 2012

Cancer cells can treat tumors

Cancer cells can treat tumors.

New on suggests that many cancer cells are equipped with a variety of suicide pill: a protein on their surfaces that gives them the power to throw an "eat me" striking to immune cells. The summons now, the researchers say, is to mentioned out how to coax cancer cells into emitting the wink rather than a dangerous "don't eat me" signal extreme no ingreece. A bone up published online Dec 22 2010 in Science Translational Medicine reports that the cells delight out the enticing "eat me" outstanding by displaying the protein calreticulin.

But another molecule, called CD47, allows most cancer cells to refrain from wrecking by sending the reverse signal: "Don't nosh me". In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 - turning off the unusual - could assistant against cancer, but mysteries remained powered by mybb smoke shops in iowa. "Many reasonable cells in the body have CD47, and yet those cells are not touched by the anti-CD47 antibody," Mark Chao, a Stanford or alumna disciple and the study's lead author, said in a university report release.

And "At that time, we knew that anti-CD47 antibody therapy selectively killed only cancer cells without being toxic to most orthodox cells, although we didn't conscious why" how much is yaz self pay?. Now, the callow research has shown that calreticulin exists in a number of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, acumen and ovarian cancers.

So "This scrutinize demonstrates that the purpose that blocking the CD47 'don't eat me' singular works to kill cancer is that leukemias, lymphomas and many downright tumors also display a calreticulin 'eat me' signal," Dr Irving Weissman, overseer of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release russain mage dubai. "The study also shows that most customary apartment populations don't evince calreticulin and are, therefore, not depleted when we air them to a blocking anti-CD47 antibody".

The next motion is to discern how calreticulin works. "We want to distinguish how it contributes to the disease process and what is circumstance in the cell that causes the protein to move to the chamber surface," Dr Ravindra Majeti, an aide-de-camp professor of hematology and study co-principal investigator, said in the release tumblr large. "Any of these mechanisms suggest covert new ways to treat the blight by interfering with those processes," Majeti said.

No comments:

Post a comment